GlaxoSmithKline Declines as FDA Clears Path for Advair Rivals, $8 Billion in Revenue Threatened
Published: Sep 10, 2013
GlaxoSmithKline Plc (GSK) fell the most in 20 months after U.S. regulators proposed a simpler route for rivals seeking to copy the company’s Advair respiratory drug, threatening almost $8 billion in revenue.
Help employers find you! Check out all the jobs and post your resume.